消息来源：COVID-19：FUJIFILM到科威特Avegan的审判
COVID-19：
FUJIFILM Holdings：
7月18日，印度的合作伙伴Reddy博士实验室Fujifilm，
他说：“我们将于7月底在科威特开始对COVID-19治疗剂Avigan进行临床试验。”
我们将在科威特进行多达1,000人的临床试验，并确认其效果。
科威特的临床试验：
FUJIFILM已授予“印度主要制药公司Reddy博士实验室对海外公司的独家开发权”，并将主要由Reddy博士进行。
约翰霍普金斯大学：
据统计，科威特的总感染人数超过了5.8万人。
如果在科威特获得了有效数据，则可以在日本使用。
联合沟通
https://this.kiji.is/657040464651830369
Fujifilm to start clinical study of COVID-19 drug Avigan in Kuwait
Fujifilm Holdings Corp.
will start a clinical study of the antiviral drug Avigan in Kuwait as early as this month in collaboration with an Indian partner company, sources close to the matter said Saturday.
India’s Dr. Reddy’s Laboratories Ltd.
is expected to mainly conduct the clinical study involving up to 1,000 people to assess its effectiveness, according to the sources.
Earlier this month, Fujifilm
said it had granted exclusive rights to Dr. Reddy’s to develop, produce and sell the potential COVID-19 treatment drug overseas, along with Dubai-based Global Response Aid.
Avigan
has been seen as a possible treatment for the COVID-19 respiratory disease caused by the novel coronavirus.
Fujifilm Toyama Chemical Co., the Japanese firm’s subsidiary that developed Avigan,
also known as favipiravir, was initially planning to conduct its clinical study targeting 96 people in Japan from late March through the end of June.
But the trial did not proceed in accordance with the plan as the number of infections in Japan was dwindling some weeks during the period.
The number of COVID-19 infections in Kuwait was more than 58,200 as of Saturday, while that of Japan came to some 24,100, according to a tally by Johns Hopkins University.
The sources said if effective data were collected during the study in Kuwait, they could be used in Japan.
Earlier this month, Fujita Health University, which has led a team carrying out clinical tests of Avigan, said again its study failed to demonstrate a clear efficacy in treating coronavirus patients at an early stage of the disease.
Dr. Reddy’s partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a potential treatment of COVID-19
https://www.drreddys.com/media/904732/press-release_dr-reddys-avigan.pdf